Follicular thyroid cancer

Clayman Thyroid Center Releases New 1 Min Video to Self-Screen for Thyroid Cancer, Among Other Resources, For Thyroid Cancer Awareness Month

Retrieved on: 
Thursday, September 22, 2022
YouTube, The Center, Papillary thyroid cancer, Health, Thyroid cancer, Graves' disease, Awareness, Woman, Thyroid, Nursing, Center, Hospital, Internet, Neoplasm, Adrenal tumor, Patient, Cancer, Diagnosis, Exocrine gland, Surgeon, HCA, Follicular thyroid cancer, Neck, Medical imaging, Trapping, Dentistry

In the new thyroid cancer self-check video , released by the Clayman Thyroid Center for Thyroid Cancer Awareness Month, Dr. Rashmi Roy will walk you through how to perform this self-check in less than one minute.

Key Points: 
  • In the new thyroid cancer self-check video , released by the Clayman Thyroid Center for Thyroid Cancer Awareness Month, Dr. Rashmi Roy will walk you through how to perform this self-check in less than one minute.
  • Previous self-check videos released by the Clayman Thyroid Center team helped countless people take a step toward advocating for their own health.
  • In addition to videos, the Clayman Thyroid Center is also publishing articles written by expert thyroid surgeons for Thyroid Cancer Awareness Month.
  • About the Clayman Thyroid Center:
    Founded by one of the nation's best-known thyroid surgeons, the Clayman Thyroid Center is the highest volume thyroid cancer referral center inthe United States.

Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois

Retrieved on: 
Thursday, February 25, 2021
Anatomy, Thyroid disease, Organ systems, Glands, Thyroid cancer, Follicular thyroid cancer, Thyroid, Medullary thyroid cancer, Yuri Nikiforov

Tom Burnell, President and CEO of Interpace Biosciences, stated, We are pleased that Blue Cross Blue Shield of Illinois, a division of one of the largest payers in United States, Health Care Services Corporation, has agreed to contract with us for our molecular tests, making them available to their members on an in-network basis.

Key Points: 
  • Tom Burnell, President and CEO of Interpace Biosciences, stated, We are pleased that Blue Cross Blue Shield of Illinois, a division of one of the largest payers in United States, Health Care Services Corporation, has agreed to contract with us for our molecular tests, making them available to their members on an in-network basis.
  • ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma.
  • ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules.
  • Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries.

Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Retrieved on: 
Thursday, February 25, 2021
Oncology, Health, FDA, General Health, Clinical trials, Pharmaceutical, Biotechnology, Anatomy, Thyroid disease, Organ systems, Glands, Thyroid cancer, Follicular thyroid cancer, Cabozantinib, Thyroid neoplasm, Thyroid nodule, Thyroid, Ipsen, Papillary thyroid cancer, COSMIC-311, Differentiated Thyroid Cancer, CABOMETYX® (cabozantinib)

In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.

Key Points: 
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies.
  • Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.
  • Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer

Retrieved on: 
Monday, December 21, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Thyroid disease, Endocrinology, Organ systems, Anatomy, Thyroid cancer, Cabozantinib, Thyroid nodule, American Thyroid Association, Follicular thyroid cancer, Papillary thyroid cancer

We are thankful to the patients, physicians and site staff who are participating in this trial during the COVID-19 pandemic.

Key Points: 
  • We are thankful to the patients, physicians and site staff who are participating in this trial during the COVID-19 pandemic.
  • COSMIC-311 is a multicenter, randomized, double-blind, placebo-controlled phase 3 pivotal trial that aimed to enroll approximately 300 patients at 150 sites globally.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies.
  • Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.

Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays

Retrieved on: 
Tuesday, July 21, 2020
Thyroid disease, Glands, Organ systems, Endocrine system, Thyroid cancer, Thyroid, Follicular thyroid cancer, Medullary thyroid cancer, Papillary thyroid cancer, Yuri Nikiforov

Sites participating in this multicentered study included Cedars-Sinai Medical Center, Jackson Thyroid & Endocrine Clinic, University of Michigan, Massachusetts General Hospital/Harvard Medical School, and the University of Arkansas for Medical Sciences.

Key Points: 
  • Sites participating in this multicentered study included Cedars-Sinai Medical Center, Jackson Thyroid & Endocrine Clinic, University of Michigan, Massachusetts General Hospital/Harvard Medical School, and the University of Arkansas for Medical Sciences.
  • ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma.
  • MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer.
  • ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules.

Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer

Retrieved on: 
Tuesday, February 25, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Thyroid disease, Glands, Organ systems, Endocrine system, Thyroid cancer, Cabozantinib, Thyroid nodule, Exelixis, American Thyroid Association, Thyroid, Papillary thyroid cancer, Follicular thyroid cancer, Differentiated Thyroid Cancer, CABOMETYX® (cabozantinib)

COSMIC-311 is a multicenter, randomized, double-blind, placebo-controlled phase 3 pivotal trial that aims to enroll approximately 300 patients at 150 sites globally.

Key Points: 
  • COSMIC-311 is a multicenter, randomized, double-blind, placebo-controlled phase 3 pivotal trial that aims to enroll approximately 300 patients at 150 sites globally.
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies.
  • Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.

Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay

Retrieved on: 
Tuesday, February 11, 2020
Glands, Organ systems, Endocrine system, Thyroid cancer, Thyroid disease, Medullary thyroid cancer, Follicular thyroid cancer, Thyroid neoplasm, Thyroid

According to Jack Stover, CEO of Interpace, We are pleased with the thorough assessment given by CMS in evaluating one of our key products with the result of improved pricing for ThyraMIR.

Key Points: 
  • According to Jack Stover, CEO of Interpace, We are pleased with the thorough assessment given by CMS in evaluating one of our key products with the result of improved pricing for ThyraMIR.
  • We believe this modification represents value-based pricing and reflects the critical impact ThyraMIR has on identifying a surgical need from surveillance.
  • ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma.
  • Interpace Pharma Solutions Is a business unit of Interpace Biosciences that provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries.

Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®

Retrieved on: 
Tuesday, December 17, 2019
Thyroid disease, Glands, Organ systems, Endocrine system, Thyroid cancer, Thyroid neoplasm, Thyroid, Follicular thyroid cancer, Medullary thyroid cancer, Papillary thyroid cancer, Computed tomography of the thyroid

This increase in reimbursement rates reflects the expansion of the ThyGeNEXT panel to aid in identifying the appropriate patients for surgery.

Key Points: 
  • This increase in reimbursement rates reflects the expansion of the ThyGeNEXT panel to aid in identifying the appropriate patients for surgery.
  • ThyGeNEXT has been covered by an existing LCD since it was launched in mid-2018 and its predecessor, ThyGenX, has been covered since 2014.
  • ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma.
  • ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules.